Physicians and Labs Can Now Screen for Chlamydia and Gonorrhea Using Liquid-based Cytology Samples Collected During Routine Cervical Cancer Screening
Durham, NC (December 7, 2009) - BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE:BDX), announced today it has received clearance from the U.S. Food and Drug Administration (FDA) to utilize its BD ProbeTec™ Chlamydia trachomatis (CT) Qx and BD ProbeTec™ Neisseria gonorrhoeae (GC) Qx Amplified DNA Assays with samples collected during women's routine liquid-based Pap testing for cervical cancer screening.
"BD is leveraging technologies and expertise across the Company to enhance disease detection and patient management in women's health," said Wayne Brinster, Vice President and General Manager, Women's Health and Cancer, BD Diagnostics."Providing physicians and laboratories with the ability to test for chlamydia and gonorrhea while screening for cervical cancer increases their efficiency, and more importantly, improves the level of information they have to make important patient care decisions."
The BD ProbeTec Qx Amplified DNA Assays are the first to receive FDA clearance for gynecological specimens collected and transported in the two leading types of liquid-based cytology (LBC) preservative media on the market today.i These include the BD SurePath™ Liquid-based Pap Test, which uses detachable-head collection devices that help ensure 100 percent of collected cells are sent to the laboratory for analysis.Only the BD SurePath Pap test has FDA-approved claims for achieving the highest increase in HSIL+ disease detection and significantly reducing unsatisfactory samples.
After collecting the LBC sample, the physicians will send it to a laboratory for testing.If the physician ordered chlamydia and gonorrhea screening, the laboratory professional trained in handling molecular diagnostic specimens will extract enough specimen from the LBC vial to run the BD ProbeTec Qx Amplified DNA Assays on the next-generation BD Viper™ System with XTR™ Technology.The remaining specimen will then be forwarded to the cytology lab for LBC slide preparation and testing.
The BD Viper System with XTR Technology enables laboratories to process a higher volume of tests automatically from swabs, urine, and now with LBC preservative media.The system requires significantly less hands-on-time and provides greater reliability than other systems. This improvement in process efficiency may lead to more timely diagnosis and treatment for the two most common sexually transmitted infections (STIs) - chlamydia and gonorrhea.
If left untreated, these infections in women can lead to pelvic inflammatory disease, infertility, ectopic pregnancy and chronic pelvic pain.ii Cytological screening of cervical specimens can aid in the prevention of cervical cancer. Co-infections with chlamydia are an epidemiologic factor associated with the risk of cervical cancer.iii According to a recent report issued by the U.S. Centers for Disease Control and Prevention, the incidence of chlamydia has never been higher, with more than 1.1 million cases reported in 2007.iv It is the most prevalent STI in the United States.
For more information on the BD Viper System with XTR Technology and the BD ProbeTec Qx Amplified DNA Assays, please visit: http://www.bd.com/ds/viper.To learn more about the BD SurePath Liquid-based Pap Test, please visit: http://www.bd.com/tripath/products/surepath.
About BD
BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.
i The FDA also cleared the BD ProbeTec Qx Amplified DNA Assays to be tested with LBC specimens collected with Hologic ThinPrep® PreservCyt® Solution.
ii U.S. Preventive Services Task Force. (2001). Screening for Chlamydial infection: recommendations and rationale. American Journal of Preventive Medicine 20 (Suppl. 3), 90-94.
iii Silins I, Ryd W, Strand A, et al. Chlamydia trachomatis infection and persistence of human papillomavirus. Int J Cancer. 2005;116(1):110-115.
iv U.S. Centers for Disease Control and Prevention. Sexually transmitted disease surveillance, (2007). Atlanta, GA: US Department of Health and Human Services, CDC; 2008. Available at http://www.cdc.gov/std/stats07/toc.htm.
This press release may contain certain forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues, products and income, or events or developments that BD expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. Factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: competitive factors; pricing and market share pressures; changes in interest or foreign currency exchange rates; difficulties inherent in product development and delays in product introductions; changes in regional, national or foreign economic conditions; increases in energy costs; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; and changes in healthcare or other governmental regulation; issuance of new or revised accounting standards, as well as other factors discussed in this press release and in BD's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.
